FDA
-
-
-
-
-
-
-
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
-
-
-
-
-
-
-
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
-
-
-
-
-
-
-
Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scient
-
-
-
-
-
-
-
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
-
-
-
-
-
-
-
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
-
-
-
-
-
-
-
Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
-
-
-
-
-
-
-
Benitec Biopharma to Present at the OPMD International Conference
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

